Tens of thousands of Americans have relied on MD Anderson in Houston to care for their loved one, especially when a cancer ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

Meetings designed to distribute grant money to fund research were canceled as part of a communications freeze at health ...

Rice University chemist and director of the university’s Synthesis X Center Han Xiao and cancer biologist Dihua Yu of The ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...

AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, today announced the dosing of the first patient in its Phase 2a study ...

New public health warnings have made drinking recommendations confusing. Is moderate alcohol use safe? Doctors share what ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

About 150,000 Americans are diagnosed annually with colorectal cancer, which occurs when cells in the colon or rectum grow ...

The study is led by Shubham Pant, MD, Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. This clinical trial ...

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...